Treating schizophrenia: the quality of evidence behind treatment recommendations and how it can improveGreg Aran, Chandler Hicks, Alexander Demand, Austin L Johnson, Jason Beaman, Yakiji Bailey, Melissa Haught, Aaron Lane, Philip Sinnett, Matt Vassar
24 July 2020
Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the mediaLisa Cosgrove, Ioana Alina Cristea, Allen F Shaughnessy, Barbara Mintzes, Florian Naudet
21 November 2019
Determinants of inter-practice variation in ADHD diagnosis and stimulant prescribing: cross-sectional database study of a national surveillance networkUy Hoang, Anthony C James, Harshana Liyanage, Simon Jones, Mark Joy, Mitch Blair, Michael Rigby, Simon de Lusignan
25 July 2019
Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical lookErlend Faltinsen, Morris Zwi, Xavier Castells, Christian Gluud, Erik Simonsen, Ole Jakob Storebø
22 May 2019
What is the threshold for a clinical minimally important drug effect?Michael P Hengartner
21 November 2018
Variation in analytic transparency in recent efficacy studies of antidepressant medicationSteven Vannoy, Madeline Brodt, Lisa Cosgrove, Allen F Shaughnessy
25 September 2018
Study supports augmentation with a non-antidepressant agent over combining or switching antidepressants in unipolar depressionStephan Köhler, Philipp Sterzer
27 July 2018
Parent-delivered CBT may reduce intervention cost, but questions arise about effectivenessGabriela M Hungerford, Lauren C Santucci, John R Weisz
4 October 2017